Andrea Landgraf Oholendt, PharmD, BCOP

Oxaliplatin is a third-generation platinum compound approved for treatment of adjuvant and metastatic colorectal cancer in combination with 5-FU and leucovorin. The addition of oxaliplatin to chemotherapy regimens for colorectal cancer has increased response rates, time to disease progression and OS. Common adverse effects associated with oxaliplatin include peripheral sensory neuropathy, hypersensitivity reactions, nausea, neutropenia, thrombocytopenia, anemia, and elevated transaminases and alkaline phosphatase.